about
A high-content image-based method for quantitatively studying context-dependent cell population dynamicsOn/off-switchable anti-neoplastic nanoarchitectureSMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancersA method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.Drug development in oncology: classical cytotoxics and molecularly targeted agents.The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathwayEmerging drugs for renal cell carcinoma.Metastasis: recent discoveries and novel treatment strategies.A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.Bayesian enrichment strategies for randomized discontinuation trialsOrganometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.Molecular targeted therapies in hepatocellular carcinomaExpanding the repertoire of RNA interference screens for developing new anticancer drug targets.Practical synthesis of a chromene analog for use as a retinoic acid receptor alpha antagonist lead compound.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.Clonal cooperativity in heterogenous cancers.Screening of Venezuelan medicinal plant extracts for cytostatic and cytotoxic activity against tumor cell lines.Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in miceBilateral Leydig cell tumor of the testis: a case report.The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme.Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
P2860
Q27329172-B195BFD1-C83F-43B5-91B0-2B665B048EBEQ28389792-4216A24A-32E4-41E4-B862-DD5451D3B38DQ28818608-46F8AA3F-E08C-4693-A4EF-9EF49361D452Q33434352-8CD66B5C-2736-4F92-ACCB-1163340BFD63Q34470371-77D4B3DA-D1C1-406B-8B67-5A7252B2E60BQ35029586-1AD5257A-4938-49C9-87A8-A2453496890FQ35827606-1B96BD12-6F9C-44BA-A2F4-A9C027E91AD7Q36010739-A12FB45D-5EAA-4A1E-A6BA-B69CEA79351CQ36302842-A9DFDA25-165C-4062-AA46-E0A185D13141Q36407511-89D0F0E5-7652-4271-860B-69C3F9B93405Q36678322-61711625-599A-47AA-8CC6-968BB34F58DAQ36886980-E751BE1B-862D-449B-92D8-8547DA8C722AQ36952837-ECF01612-7100-4919-80B8-3D3AF0F93FC7Q37003665-FDB2B102-697B-4A19-8534-1A866B46B436Q37008841-A3AD0531-95CE-4E8A-A89E-19AE64315DB2Q37319326-E394466E-EF74-4375-A9BB-8A6014CE5A65Q37899223-C0F66966-0EA4-4BD7-8016-FF5E3F83AD20Q38838285-90C35789-A05E-4B35-B75A-9B57BA6CA49AQ38943125-F61BB796-B555-4B34-8126-D6A78513B90EQ39339495-5DB3E3FB-C7CE-4D92-8155-91593B106688Q41528130-8ED0882F-94BF-4491-ACFA-C0A6D98EA751Q41592725-C38BC5DE-5F91-4417-9CA3-A5FF1CA8FA31Q43121176-AAB6742A-9ADB-4C94-943E-26FF9C5AEEF6Q43815970-5F295813-B8BE-4AEC-AE0E-C1E87D0DE9C8Q46099628-4D9884E8-B000-4017-9682-6D7792A97591Q47292301-7BFF940E-D344-4F59-89F3-C425FB1CD6E9Q52297317-39B2822A-950A-4AD0-8435-5D34B23FEF6B
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rethinking clinical trials for cytostatic drugs.
@ast
Rethinking clinical trials for cytostatic drugs.
@en
type
label
Rethinking clinical trials for cytostatic drugs.
@ast
Rethinking clinical trials for cytostatic drugs.
@en
prefLabel
Rethinking clinical trials for cytostatic drugs.
@ast
Rethinking clinical trials for cytostatic drugs.
@en
P2860
P356
P1476
Rethinking clinical trials for cytostatic drugs.
@en
P2093
Andrew W Millar
Kevin P Lynch
P2860
P2888
P304
P356
10.1038/NRC1124
P407
P577
2003-07-01T00:00:00Z